BenevolentAI Investor Conference Presentation Deck
Delivering on Strategic Plan to Maintain Position as One of
the Leaders in Al Driven Drug Discovery & TargetID
●
●
End-to-End
Drug Discovery
MERCK
Collaboration
New multi-year tech-
enabled collaboration
Commercial validation
of our End-to-End Drug
Discovery platform
BenevolentAl to
identify and develop
innovative compounds
●
●
●
88
Preclinical & Clinical
Development Pipeline
Pipeline Assets
BEN-8744 for ulcerative
colitis in a Phase I
clinical trial since
August 2023, with
topline data readout
expected in Q1 2024
BEN-28010 for GBM
now IND ready
BEN-34712 for ALS in
IND-enabling studies
●
●
db
Knowledge
Exploration
New Knowledge
Exploration Tools
Initial product
development
substantially completed
User testing underway,
including with potential
customers and partners
BenevolentAl Proprietary
●
●
Business
Operations
Leadership
François Nader Chair
assumed role as Acting
CEO
Catherine Isted
appointed as Chief
Financial Officer
. Christina Busmalis
appointed as Chief
Revenue Officer
●
$
Business
Operations
Business
Right-Sized
Cash runway extended
to at least Mid 2025
Key skills, expertise
and capabilities
retained
Benevolent 15View entire presentation